Diabetes Care Drugs Companies (2024 - 2029)

Diabetes Care Drugs Market Companies Summary

The diabetes care drugs market saw significant changes due to the COVID-19 pandemic, highlighting the potential for advancements in diabetes care. These advancements include virtual consultations between healthcare professionals and individuals with diabetes and the use of diabetes technology. The crisis led to increased interest in remote care, removal of regulatory barriers, and the use of personal blood glucose meters and continuous glucose monitoring devices in hospitals. The high prevalence of diabetes among individuals hospitalized with COVID-19 emphasized the significance of diabetes care devices. The market is moderately fragmented, with a few significant and generic players dominating. The insulin drugs and Sglt-2 drugs market are dominated by a few major players, while the market for oral drugs comprises more generic players. The intensity of competition among the players is high, with each player striving to develop new drugs and offer them at competitive pricing. To increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.